Highlights ABVC BioPharma, Inc.

Equities

ABVC

US00091F3047

Real-time Estimate Cboe BZX Other stock markets 12:55:04 17/05/2024 am IST			5-day change	1st Jan Change
1.065 ^USD	-1.39%		-2.73%	-7.76%

09/05	Abvc Biopharma, Inc. Enters into A Definitive Agreement with Oncox Biopharma, Inc	CI
10/04	ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Abvc Biopharma, Inc. Enters into A Definitive Agreement with Oncox Biopharma, Inc	09/05	CI
ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc	10/04	CI
ABVC BioPharma, Inc. and BioFirst Corporation Enter Global Licensing Agreement with ForSeeCon Eye Corporation	26/03	CI
ABVC BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03	CI
ABVC BioPharma Signs Licensing Deal With Senior Paradise	15/02	MT
ABVC BioPharma, Inc. Executes a Definitive Agreement to Receive License Fees of $3 Million and Royalties of 2% on Future Revenue	15/02	CI
ABVC BioPharma, Inc. Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study	07/12	CI
ABVC BioPharma, Inc. Enters Definitive Agreement with Licensing Income Worth $467 Million and Royalties Up to $200 Million	16/11	CI
Earnings Flash (ABVC) ABVC BIOPHARMA Reports Q3 Revenue $15,884	15/11	MT
ABVC BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
ABVC BioPharma Enters Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million	26/23/26	CI
Abvc Biopharma, Inc. Announces Completion of Subject Recruitment for Interim Analysis on Adhd Phase Iib Clinical Study	17/23/17	CI
ABVC BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
ABVC BioPharma, Inc. Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration	03/23/03	CI
ABVC BioPharma, Inc. Announces the Signing of A Legally Binding Term Sheet with Xinnovation Therapeutics Co., Ltd	01/23/01	CI
ABVC BioPharma to Acquire Stake in Chinese Real Estate For Strategic Investments	26/23/26	MT
ABVC BioPharma Sets 1-for-10 Reverse Stock Split	24/23/24	MT
ABVC BioPharma, Inc. Announces Vitargus®? Phase II Study Receives Ethical Approval At Sydney Eye Hospital in Australia	22/23/22	CI
ABVC BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
ABVC BioPharma, Inc. Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center	10/23/10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ABVC BioPharma, Inc.

Equities

ABVC

US00091F3047

Highlights

Filters